Abstract
During the past 20 years, the advent of neoadjuvant, primary, and adjuvant concurrent chemoradiotherapy has improved cancer care dramatically. Significant contributions have been made by technological improvements in radiotherapy, as well as by the introduction of novel chemotherapy agents and dosing schedules. This article will review the rationale for the use of concurrent chemoradiotherapy for treating malignancies. The molecular basis and mechanisms of action of combining classic cytotoxic agents (e.g. platinum-containing drugs, taxanes, etc.) and novel agents (e.g. tirapazamine, EGFR inhibitors and other targeted agents) with radiotherapy will be examined. This article is part one of two articles. In the subsequent article, the general principles outlined here will be applied to head and neck cancer, in which the impact of concurrent chemoradiotherapy is particularly evident.
Key Points
-
Concurrent chemoradiotherapy has improved cancer care during the past two decades in multiple diseases, and can be used in the neoadjuvant, primary (definitive), or adjuvant setting
-
Chemotherapy or targeted agents can increase the efficacy of radiation
-
Radiosensitizing effects (interaction within the radiation field) can be additive or supra-additive
-
Multiple mechanisms underlie radiosensitizing properties of chemotherapeutic agents and include increased radiation damage, inhibition of DNA repair, cell-cycle synchronization, increased cytotoxicity against hypoxic cells, inhibition of prosurvival pathways, and abrogation of rapid tumor cell repopulation
-
Radioresistance occurs through multiple mechanisms, such as a large tumor burden, hypoxia, rapid tumor cell repopulation, as well as the constitutive or acquired activation of radioresistance signaling pathways
-
In addition to the classic chemotherapeutic agents with radiosensitizing properties (i.e. cisplatin and paclitaxel), several novel agents show promising interactions with radiation (e.g. EGFR inhibitors, pemetrexed, tirapazamine, and potentially several other targeted therapies)
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Steel GG and Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85–91
Brizel DM et al. (2000) Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18: 3339–3345
Buentzel J et al. (2006) Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 64: 684–691
Komaki R et al. (2004) Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58: 1369–1377
Malik R et al. (2005) Meta-analysis of the effect of amifostine on response rates in advanced non-small cell lung cancer patients treated on randomized trials. Int J Radiat Oncol Biol Phys 63 (Suppl 1): S117
Sasse AD et al. (2006) Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int J Radiat Oncol Biol Phys 64: 784–791
Grdina DJ et al. (2002) Radioprotectants: current status and new directions. Oncology 63 (Suppl 2): S2–S10
Stiff PJ et al. (2006) Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol [doi: 10.1200/JCO.2005.02.8340]
Rosen LS et al. (2006) Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 24: 5194–5200
Giocanti N et al. (1993) DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide. Cancer Res 53: 2105–2111
Hennequin C and Favaudon V (2002) Biological basis for chemo-radiotherapy interactions. Eur J Cancer 38: 223–230
Chou TC and Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27–55
Reynolds CP and Maurer BJ (2005) Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol Med 110: 173–183
Teicher BA (2003) Assays for in vitro and in vivo synergy. Methods Mol Med 85: 297–321
White DB et al. (2003) A new nonlinear mixture response surface paradigm for the study of synergism: a three drug example. Curr Drug Metab 4: 399–409
Coleman CN (1988) Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity. J Natl Cancer Inst 80: 310–317
Gray LH et al. (1953) The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26: 638–648
Kumar P (2000) Tumor hypoxia and anemia: impact on the efficacy of radiation therapy. Semin Hematol 37: 4–8
Overgaard J et al. (1989) Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 16: 1065–1068
Moulder JE and Rockwell S (1984) Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 10: 695–712
Terasima T and Tolmach LJ (1963) X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells. Science 140: 490–492
Fowler JF and Lindstrom MJ (1992) Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 23: 457–467
Trott KR and Kummermehr J (1985) What is known about tumour proliferation rates to choose between accelerated fractionation or hyperfractionation? Radiother Oncol 3: 1–9
Krause M et al. (2005) Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother Oncol 76: 162–167
Grillo-Ruggieri F and Mantello G (2004) Is one Gy equal to one Gy after treatment interruptions? Rays 29: 275–278
Schmidt-Ullrich RK et al. (1999) Molecular mechanisms of radiation-induced accelerated repopulation. Radiat Oncol Investig 7: 321–330
West CM et al. (1997) The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br J Cancer 76: 1184–1190
Deacon J et al. (1984) The radioresponsiveness of human tumours and the initial slope of the cell survival curve. Radiother Oncol 2: 317–323
Dey S et al. (2003) Low-dose fractionated radiation potentiates the effects of paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. Clin Cancer Res 9: 1557–1565
Nix PA et al. (2004) Radioresistant laryngeal cancer: beyond the TNM stage. Clin Otolaryngol Allied Sci 29: 105–114
Smith BD and Haffty BG (1999) Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma. Radiat Oncol Investig 7: 125–144
Aebersold DM et al. (2001) Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. Int J Cancer 96: 41–54
Uchida D et al. (2001) Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int J Cancer 93: 489–496
Khodarev NN et al. (2004) STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci USA 101: 1714–1719
Bennett CB et al. (1993) Lethality induced by a single site-specific double-strand break in a dispensable yeast plasmid. Proc Natl Acad Sci USA 15: 13–17
Ward JF (1998) Nature of lesions formed by ionising radiation. In DNA damage and repair: DNA repair in higher eukaryotes, 65–84 (Eds Nickoloff JA and Hoekstra MF). Totowa, NJ: Humana Press
Begg AC (1990) Cisplatin and radiation: interaction probabilities and therapeutic possibilities. Int J Radiat Oncol Biol Phys 19: 1183–1189
Yang LX et al. (1995) Production of DNA double-strand breaks by interactions between carboplatin and radiation: a potential mechanism for radiopotentiation. Radiat Res 143: 309–315
Sinclair WK and Morton RA (1966) X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 29: 450–474
Terasima T and Tolmach LJ (1961) Changes in x-ray sensitivity of HeLa cells during the division cycle. Nature 190: 1210–1211
Wilson GD et al. (2006) Biologic basis for combining drugs with radiation. Semin Radiat Oncol 16: 2–9
Hei TK et al. (1994) Taxol and ionizing radiation: interaction and mechanisms. Int J Radiat Oncol Biol Phys 29: 267–271
Stromberg JS et al. (1995) Lack of radiosensitization after paclitaxel treatment of three human carcinoma cell lines. Cancer 75: 2262–2268
Vaupel P (2004) Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14: 198–206
Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721–732
Milas L et al. (1995) Tumor reoxygenation as a mechanism of taxol-induced enhancement of tumor radioresponse. Acta Oncol 34: 409–412
Kim JJ and Tannock IF (2005) Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5: 516–525
Liang K et al. (2003) The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 57: 246–254
Bonner JA et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567–578
Spring PM et al. (2004) Low dose fractionated radiation potentiates the effects of taxotere in nude mice xenografts of squamous cell carcinoma of head and neck. Cell Cycle 3: 479–485
Vokes EE and Weichselbaum RR (1990) Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol 8: 911–934
Richmond RC (1984) Toxic variability and radiation sensitization by dichlorodiammineplatinum(II) complexes in Salmonella typhimurium cells. Radiat Res 99: 596–608
Yang LX et al. (1995) Irradiation enhances cellular uptake of carboplatin. Int J Radiat Oncol Biol Phys 33: 641–646
Amorino GP et al. (1999) Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition. Int J Radiat Oncol Biol Phys 44: 399–405
Moreland NJ et al. (1999) Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin. Cancer Res 59: 2102–2106
Dolling JA et al. (1999) Cisplatin-modification of DNA repair and ionizing radiation lethality in yeast, Saccharomyces cerevisiae. Mutat Res 433: 127–136
Lawrence TS et al. (1997) Fluoropyrimidine-radiation interactions in cells and tumors. Semin Radiat Oncol 7: 260–266
McGinn CJ and Lawrence TS (2001) Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol 11: 270–280
Pinedo HM and Peters GF (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6: 1653–1664
Sawada N et al. (1999) X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 5: 2948–2953
Hui YF and Reitz J (1997) Gemcitabine: a cytidine analogue active against solid tumors. Am J Health Syst Pharm 54: 162–170
Crane CH et al. (2002) Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 52: 1293–1302
Blackstock AW et al. (2005) Initial pulmonary toxicity evaluation of chemoradiotherapy (CRT) utilizing 74 Gy 3-dimensional (3-D) thoracic radiation in stage III non-small cell lung cancer (NSCLC): a Cancer and Leukemia Group B (CALGB) randomized phase II trial [abstract #7060]. Presented at the 2005 ASCO annual meeting, Orlando, FL
Talamonti MS et al. (2006) A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 13: 150–158
Lawrence TS et al. (2003) The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 13: 13–21
Lawrence TS et al. (1997) Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine). Clin Cancer Res 3: 777–782
Shewach DS and Lawrence TS (1996) Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs 14: 257–263
Bischof M et al. (2002) Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro. Int J Radiat Oncol Biol Phys 52: 1381–1388
Bischof M et al. (2003) Radiosensitization by pemetrexed of human colon carcinoma cells in different cell cycle phases. Int J Radiat Oncol Biol Phys 57: 289–292
Seiwert TY et al. (2005) A phase I dose-escalating study of combination pemetrexed-based chemotherapy and concomitant radiotherapy for locally advanced or metastatic non-small cell lung or esophageal cancer [abstract #7062]. Presented at the 2005 ASCO annual meeting, Orlando, FL
Vokes EE et al. (1992) Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. Semin Oncol 19: 53–58
Kuo ML et al. (1997) The interaction of hydroxyurea and ionizing radiation in human cervical carcinoma cells. Cancer J Sci Am 3: 163–173
Prados MD et al. (1998) Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. Int J Radiat Oncol Biol Phys 40: 57–63
Leyden D et al. (2000) Hydroxyurea and trimidox enhance the radiation effect in human pancreatic adenocarcinoma cells. Anticancer Res 20: 133–138
Schiff PB and Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561–1565
Hennequin C et al. (1995) S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer 71: 1194–1198
Steel GG (1994) Cell synchronization unfortunately may not benefit cancer therapy. Radiother Oncol 32: 95–97
Ingram ML and Redpath JL (1997) Subadditive interaction of radiation and Taxol in vitro. Int J Radiat Oncol Biol Phys 37: 1139–1144
Heinrich MC et al. (1998) DNA cross-linker-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint function. Blood 91: 275–287
Sugiyama K et al. (2000) UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation. Int J Cancer 85: 703–709
Budach W et al. (2002) Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma. Br J Cancer 86: 470–476
Wouters BG et al. (1999) Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer. Ann Oncol 10 (Suppl 5): S29–S33
Brown JM and Lemmon MJ (1990) Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 50: 7745–7749
Lartigau E and Guichard M (1995) Does tirapazamine (SR-4233) have any cytotoxic or sensitizing effect on three human tumour cell lines at clinically relevant partial oxygen pressure? Int J Radiat Biol 67: 211–216
Lambin P et al. (1992) The effect of the hypoxic cell drug SR-4233 alone or combined with the ionizing radiations on two human tumor cell lines having different radiosensitivity. Radiother Oncol 24: 201–204
Brown JM and Koong A (1991) Therapeutic advantage of hypoxic cells in tumors: a theoretical study. J Natl Cancer Inst 83: 178–185
Brown JM (1993) SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67: 1163–1170
Brown JM (1999) The hypoxic cell: a target for selective cancer therapy—eighteenth Bruce F Cain Memorial Award lecture. Cancer Res 59: 5863–5870
Wouters BG et al. (2001) Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine. Cancer Res 61: 145–152
Patel M et al. (2003) Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 61: 203–207
Hickman MJ and Samson LD (1999) Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc Natl Acad Sci USA 96: 10764–10769
Roos W et al. (2004) Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. Oncogene 23: 359–367
Hermisson M et al. (2006) O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 96: 766–776
Wick W et al. (2002) Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res 62: 1915–1919
Beauchesne P (2002) Promising survival and concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20: 3180–3181
Wedge SR et al. (1997) In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 8: 92–97
van Rijn J et al. (2000) Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 47: 779–784
Salama JK (2004) Intensity-modulated radiation therapy in gynecologic malignancies. Curr Treat Options Oncol 5: 97–108
Ma BB et al. (2003) Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol 21: 2760–2776
Ang KK et al. (2004) Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 58: 959–965
Pal SK and Pegram M (2005) Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy. Anticancer Drugs 16: 483–494
Dent P et al. (1999) Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10: 2493–2506
Chinnaiyan P et al. (2005) Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65: 3328–3335
Bandyopadhyay D (1998) Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 273: 1568–1573
Dittmann KH et al. (2001) Characterization of the amino acids essential for the photo- and radioprotective effects of a Bowman-Birk protease inhibitor-derived nonapeptide. Protein Eng 14: 157–160
Milas L et al. (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6: 701–708
Bonner JA et al. (2000) Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 18 (Suppl): 47S–53S
Folkman J (2006) Angiogenesis. Annu Rev Med 57: 1–18
Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58–62
Wachsberger P et al. (2003) Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 9: 1957–1971
Murata R et al. (1997) An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys 37: 1107–1113
Mauceri HJ et al. (1998) Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394: 287–291
Ning S et al. (2002) The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 157: 45–51
Hanna NN et al. (2000) Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J 6: 287–293
Birchmeier C et al. (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915–925
Lal B et al. (2005) Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin Cancer Res 11: 4479–4486
Senzer N et al. (2005) Updated response and survival data for TNFerade combined with chemoradiation in the treatment of locally advanced pancreatic cancer (LAPC) [abstract #4097]. Presented at the 2005 ASCO annual meeting, Orlando, FL
Russo SM et al. (2001) Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 50: 183–193
Shinohara ET et al. (2005) Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 24: 5414–5422
Nishimura Y (2004) Rationale for chemoradiotherapy. Int J Clin Oncol 9: 414–420
Pigott K et al. (1995) Where exactly does failure occur after radiation in head and neck cancer? Radiother Oncol 37: 17–19
Shukovsky LJ (1970) Dose, time, volume relationships in squamous cell carcinoma of the supraglottic larynx. Am J Roentgenol Radium Ther Nucl Med 108: 27–29
Cook JA et al. (2004) Oxidative stress, redox, and the tumor microenvironment. Semin Radiat Oncol 14: 259–266
Milosevic M et al. (2004) The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 14: 249–258
Roh HD et al. (1991) Interstitial hypertension in carcinoma of uterine cervix in patients: possible correlation with tumor oxygenation and radiation response. Cancer Res 51: 6695–6698
Taghian AG et al. (2005) Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol 23: 1951–1961
Koukourakis MI et al. (2002) Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 53: 1192–1202
Suwinski R and Withers HR (2003) Time factor and treatment strategies in subclinical disease. Int J Radiat Biol 79: 495–502
Holsinger FC et al. (2003) Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer. Clin Cancer Res 9: 3183–3189
Knecht R et al. (2003) EGFR antibody-supplemented TPE-chemotherapy: preclinical investigations to a novel approach for head and neck cancer induction treatment. Anticancer Res 23: 4789–4795
Niwa H et al. (2003) Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Clin Cancer Res 9: 5028–5035
Cohen EE (2005) Integration of Gefitinib (G), into a Concurrent Chemoradiation (CRT) Regimen Followed by G Adjuvant Therapy in Patients with Locally Advanced Head and Neck Cancer (HNC)—a Phase II Trial [abstract #5506]. J Clin Oncol 23 (Suppl): 16S
Acknowledgements
The authors would like to acknowledge the generous help of Dr Blase Polite and Dr Samir Undevia in reviewing organ-specific data.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
EE Vokes has been a consultant for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, ImClone, OSI and sanofi-aventis. The other authors declared they have no competing interests.
Rights and permissions
About this article
Cite this article
Seiwert, T., Salama, J. & Vokes, E. The concurrent chemoradiation paradigm—general principles. Nat Rev Clin Oncol 4, 86–100 (2007). https://doi.org/10.1038/ncponc0714
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0714
This article is cited by
-
Injectable hydrogel systems for local cancer therapy
Journal of Pharmaceutical Investigation (2024)
-
Impact of fractionated cisplatin and radiation treatment on cell growth and accumulation of DNA damage in two normal cell types differing in origin
Scientific Reports (2023)
-
Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment
BMC Cancer (2022)
-
Enhancement of IUdR Radiosensitization in Cancer Therapy by Low-Energy Transmission X Ray Irradiation
Journal of Medical and Biological Engineering (2021)
-
A novel evaluation method for Ki-67 immunostaining in paraffin-embedded tissues
Virchows Archiv (2021)